FUTURE FDA SUPAC PROJECTS
This article was originally published in The Gold Sheet
...are likely to address cross-cutting issues rather than specific dosage forms, following the lead of the guidance for lab site changes. Post-approval changes guidances already in the pipeline include a mix of dosage form-specific (sterile solutions and transdermals) and issue-oriented (packaging) docu-ments. Comparability protocols will be addressed in a joint CDER/CBER guidance as another mechanism to facilitate post-approval changes. A rewrite of the manufacturing change regulations and of SUPAC-Immediate Release is slowing the work on other PAC projects. ANDA sponsors hold a four-to-one edge over NDA sponsors in SUPAC-IR filings. While CDER reviews the industry comments on the first section of the bulk active post-approval changes document, a draft of BACPAC II is beginning to take shape. Relief for DMF holders is one industry concern.
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.